Android app Apple app link

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

By Yahoo! Finance   |   1 month ago
Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience's drug, nimacimab, did not lead to significant weight loss in overweight adults in a recent study, causing a 66% drop in its shares. When combined with semaglutide, the drug showed more promising results, with patients losing 13.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.